Drug trial aims to stop lung cancer before it starts
NCT ID NCT03347838
Summary
This study is testing whether a drug called nivolumab can reverse abnormal, pre-cancerous cells in the lungs of high-risk current and former smokers. The goal is to see if boosting the immune system can prevent these abnormal cells from turning into lung cancer. Participants receive four doses of the drug over eight weeks and undergo lung biopsies to check for changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOBACCO SMOKING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Denver VA Hospital
Denver, Colorado, 80220, United States
-
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.